Abbott Laboratories $ABT Shares Sold by Axxcess Wealth Management LLC

Axxcess Wealth Management LLC lessened its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 67.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 30,628 shares of the healthcare product maker's stock after selling 64,579 shares during the period. Axxcess Wealth Management LLC's holdings in Abbott Laboratories were worth $3,027,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Bank of America Corp DE purchased a new stake in shares of Abbott Laboratories in the second quarter valued at approximately $1,603,607,000. Legal & General Group Plc bought a new position in Abbott Laboratories in the second quarter worth approximately $1,082,524,000. Flossbach Von Storch SE purchased a new position in Abbott Laboratories during the 2nd quarter worth $902,938,000. Jupiter Topco LLC purchased a new position in Abbott Laboratories during the 2nd quarter worth $732,788,000. Finally, BlackRock Inc. raised its position in Abbott Laboratories by 4.6% during the 2nd quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker's stock valued at $13,843,610,000 after purchasing an additional 6,769,518 shares in the last quarter. Institutional investors own 75.18% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Weiss Ratings upgraded Abbott Laboratories from a "hold (c-)" rating to a "hold (c)" rating in a report on Friday, September 18th. Citigroup cut their price target on Abbott Laboratories from $125.00 to $122.00 and set a "buy" rating on the stock in a research note on Thursday. Royal Bank Of Canada decreased their price objective on Abbott Laboratories from $130.00 to $125.00 and set an "outperform" rating for the company in a report on Thursday. Wells Fargo & Company upped their price objective on shares of Abbott Laboratories from $112.00 to $119.00 and gave the stock an "overweight" rating in a research note on Thursday. Finally, BTIG Research cut their target price on shares of Abbott Laboratories from $134.00 to $125.00 and set a "buy" rating on the stock in a research report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $118.32.

Abbott Laboratories Trading Up 2.1%

Shares of NYSE ABT opened at $102.64 on Friday. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $132.02. The business has a fifty day moving average price of $105.30 and a 200 day moving average price of $98.28. The stock has a market capitalization of $177.61 billion, a P/E ratio of 18.68, a price-to-earnings-growth ratio of 1.86 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.42. The company had revenue of $13.01 billion for the quarter, compared to analyst estimates of $12.99 billion. Abbott Laboratories had a return on equity of 17.97% and a net margin of 9.75%. The firm's quarterly revenue was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.30 earnings per share. Equities research analysts expect that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a $0.63 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.5%. Abbott Laboratories's payout ratio is presently 81.55%.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott reported third-quarter adjusted EPS of $1.42, in line with the main consensus estimate, and revenue of $13.01 billion, slightly above the $12.99 billion estimate. Reported sales rose 14.5% year over year, while comparable sales increased 7%. Abbott third-quarter results
• Positive Sentiment: Abbott reaffirmed its full-year adjusted EPS guidance, and analysts continue to see upside. Wells Fargo raised its price target to $119, while Robert W. Baird raised its target to $123. Citigroup, RBC, JPMorgan, TD Cowen and BTIG lowered targets but retained bullish ratings, including “buy,” “outperform” or “overweight.”
• Positive Sentiment: The company received European approval for its Cologuard Plus colorectal-cancer screening test, expanding the potential market for its diagnostics portfolio. Abbott Cologuard Plus European approval
• Neutral Sentiment: Abbott plans a tax-free separation of its approximately $8.5 billion Nutrition business into an independent, publicly traded company by the end of 2027. Management says the move could give both businesses more focused investment strategies, but investors face execution, allocation and valuation uncertainty during the transition. Abbott Nutrition separation announcement
• Negative Sentiment: Abbott reduced its 2026 sales-growth outlook, citing pressure from diabetes-related pricing and weakness in parts of its electrophysiology and medical-device businesses. This softer outlook overshadowed the quarterly revenue performance and led several analysts to trim price targets. Abbott lowers 2026 sales forecast
• Negative Sentiment: India’s food regulator issued a notice involving infant-formula claims related to Nestlé India and Abbott, creating a limited regulatory overhang for Abbott’s Nutrition operations. India infant-formula regulatory notice

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women's health and cardiometabolic care.

The company's nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.